These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 25084805)

  • 1. cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?
    Gaule PB; Crown J; O'Donovan N; Duffy MJ
    Expert Opin Ther Targets; 2014 Sep; 18(9):999-1009. PubMed ID: 25084805
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MET is a potential target for use in combination therapy with EGFR inhibition in triple-negative/basal-like breast cancer.
    Kim YJ; Choi JS; Seo J; Song JY; Lee SE; Kwon MJ; Kwon MJ; Kundu J; Jung K; Oh E; Shin YK; Choi YL
    Int J Cancer; 2014 May; 134(10):2424-36. PubMed ID: 24615768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting c-Met in triple negative breast cancer: preclinical studies using the c-Met inhibitor, Cpd A.
    Breen L; Gaule PB; Canonici A; Walsh N; Collins DM; Cremona M; Hennessy BT; Duffy MJ; Crown J; Donovan NO; Eustace AJ
    Invest New Drugs; 2020 Oct; 38(5):1365-1372. PubMed ID: 32318883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting CD73 and downstream adenosine receptor signaling in triple-negative breast cancer.
    Allard B; Turcotte M; Stagg J
    Expert Opin Ther Targets; 2014 Aug; 18(8):863-81. PubMed ID: 24798880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. cMET as a potential therapeutic target in gastric cancer (Review).
    Teng L; Lu J
    Int J Mol Med; 2013 Dec; 32(6):1247-54. PubMed ID: 24141315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dasatinib is synergistic with cetuximab and cisplatin in triple-negative breast cancer cells.
    Kim EM; Mueller K; Gartner E; Boerner J
    J Surg Res; 2013 Nov; 185(1):231-9. PubMed ID: 23899511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P53 mutations in triple negative breast cancer upregulate endosomal recycling of epidermal growth factor receptor (EGFR) increasing its oncogenic potency.
    Shapira I; Lee A; Vora R; Budman DR
    Crit Rev Oncol Hematol; 2013 Nov; 88(2):284-92. PubMed ID: 23755891
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress of antibody-based inhibitors of the HGF-cMET axis in cancer therapy.
    Kim KH; Kim H
    Exp Mol Med; 2017 Mar; 49(3):e307. PubMed ID: 28336955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.
    Ferrucci A; Moschetta M; Frassanito MA; Berardi S; Catacchio I; Ria R; Racanelli V; Caivano A; Solimando AG; Vergara D; Maffia M; Latorre D; Rizzello A; Zito A; Ditonno P; Maiorano E; Ribatti D; Vacca A
    Clin Cancer Res; 2014 Nov; 20(22):5796-807. PubMed ID: 25212607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting MET and EGFR crosstalk signaling in triple-negative breast cancers.
    Linklater ES; Tovar EA; Essenburg CJ; Turner L; Madaj Z; Winn ME; Melnik MK; Korkaya H; Maroun CR; Christensen JG; Steensma MR; Boerner JL; Graveel CR
    Oncotarget; 2016 Oct; 7(43):69903-69915. PubMed ID: 27655711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting Epidermal Growth Factor Receptor in triple negative breast cancer: New discoveries and practical insights for drug development.
    Costa R; Shah AN; Santa-Maria CA; Cruz MR; Mahalingam D; Carneiro BA; Chae YK; Cristofanilli M; Gradishar WJ; Giles FJ
    Cancer Treat Rev; 2017 Feb; 53():111-119. PubMed ID: 28104566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The clinical and functional significance of c-Met in breast cancer: a review.
    Ho-Yen CM; Jones JL; Kermorgant S
    Breast Cancer Res; 2015 Apr; 17(1):52. PubMed ID: 25887320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting triple negative breast cancer with histone deacetylase inhibitors.
    Fedele P; Orlando L; Cinieri S
    Expert Opin Investig Drugs; 2017 Nov; 26(11):1199-1206. PubMed ID: 28952409
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer.
    Weng TH; Yao MY; Xu XM; Hu CY; Yao SH; Liu YZ; Wu ZG; Tang TM; Fu PF; Wang MH; Yao HP
    Cancer Res Treat; 2020 Jul; 52(3):973-986. PubMed ID: 32324988
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cabozantinib (XL184) Inhibits Growth and Invasion of Preclinical TNBC Models.
    Sameni M; Tovar EA; Essenburg CJ; Chalasani A; Linklater ES; Borgman A; Cherba DM; Anbalagan A; Winn ME; Graveel CR; Sloane BF
    Clin Cancer Res; 2016 Feb; 22(4):923-34. PubMed ID: 26432786
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification.
    Guestini F; McNamara KM; Ishida T; Sasano H
    Expert Opin Ther Targets; 2016 Jun; 20(6):705-20. PubMed ID: 26607563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular pathways: PI3K pathway targets in triple-negative breast cancers.
    Gordon V; Banerji S
    Clin Cancer Res; 2013 Jul; 19(14):3738-44. PubMed ID: 23748695
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer.
    Montero JC; Esparís-Ogando A; Re-Louhau MF; Seoane S; Abad M; Calero R; Ocaña A; Pandiella A
    Oncogene; 2014 Jan; 33(2):148-56. PubMed ID: 23246963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The emerging role of MET/HGF inhibitors in oncology.
    Scagliotti GV; Novello S; von Pawel J
    Cancer Treat Rev; 2013 Nov; 39(7):793-801. PubMed ID: 23453860
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing biomarkers to predict benefit from HGF/MET pathway inhibitors.
    Koeppen H; Rost S; Yauch RL
    J Pathol; 2014 Jan; 232(2):210-8. PubMed ID: 24105670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.